• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery • Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks • Manufacturing Facility Now Fully Scaled Up and Capable of Supporting at Least First 30 Months

PETAH TIKVA, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its first quarter 2021 financial

PETAH TIKVA, Israel, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymond James 42 nd

Top-line Data Anticipated by Year End   2021 Enrollment Also Continues to Progress in   Company’s Second Phase 3 Clinical Trial ,   SHIELD I I PETAH TIKVA, Israel , Feb. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical

100   Patient s Enrolled into Phase 3 SHIELD I and SHIELD II   Trial s   of D-PLEX 100 in Abdominal Surgery Recently Initiated Phase 3 SHIELD II Trial Granted Breakthrough Therapy Designation from FDA for D-PLEX 100 for Prevention of SSIs in P atients U ndergoing E lective C olorectal S urgery

PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report